CN EN

About Us

Home>Board of directors

Management Team

  • Executive Director and Chairwoman: Miss Tse, Theresa
    is the chairwoman of the Board, an executive director, and the chairwoman of the executive board committee and the nomination committee of Sino Biopharmaceutical Co., Ltd. since 2015. In 2017, she served as the director of CT Tianqing and the vice chairwoman of Beijing Tide, and a member of the first and second board of directors of Beijing Chia Tai Charity Foundation. Ms. Tse has a Bachelor of Science Degree in economics from the Wharton School of business at the University of Pennsylvania. She focused on the study of financial and health management. As a new generation business leader, Ms. Tse was recognised as one of the“Most Outstanding Business Women in China” by Forbes China online in 2018 and 2019.
  • Executive Director and Senior Vice Chairman: Mr. Tse Ping
    is the founding chairman of the Company and now serves as senior vice chairman of the Company. With more than 27 years of extensive experience in investment and management in the pharmaceutical industry in China, he is currently a director of CT Tianqing, Beijing Tide, NJCTT, Jiangsu CT Fenghai, Jiangsu CT Qingjiang, and CP Qingdao. He is also a director of Shanghai Fortune World Development Co., Ltd., Tianjin Chiatai Feed Tech Co., Ltd., SYN Energy Technology Co., Ltd., Chia Tai Oversea Chinese Realty Development Co., Ltd., and Karolinska Development AB (publ) (listed on NASDAQ Stockholm Exchange). Mr. Tse still serves as a director of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. and a council member of the Association of Pharmaceutical Biotechnology of China. Soon after the adoption of the open-up and reform policy by China, Mr. Tse started to develop his investment and business in China. He has been engaged in the pharmaceutical industry since 1991, having made equity investments in a dozen or so enterprises, and is one of the earliest and the most successful overseas investors in the PRC pharmaceutical industry. Led by Mr. Tse, CP Pharmaceutical Group now has developed to a large integrated life and healthcare enterprise, and its Hong Kong listed flagship Sino Biopharmaceutical Limited becomes a constituent of the Heng Seng Index, holding a leading position among all pharmaceutical stocks in the market and owning a number of national key high-technology enterprises. Adhering to the concept of technology innovation and building upon research and development system based on originality as well as imitation, the Group strives to develop international level, high-end biological drugs and innovative drugs and to achieve breakthroughs in different areas including medical services, medical equipment, the greater health fields, and mergers and acquisitions, and becomes an innovation driven life and healthcare enterprise with its business encompassing a fully integrated industry chain which spans from research and development to manufacture and sales of pharmaceutical products and covers management of chronic diseases and healthcare. Since incorporation, Sino Biopharmaceutical Limited continues to break its own record in terms of revenue and net profit, and was ranked one of the “Asia’s Fab 50 Companies” by Forbes Asia for three consecutive years from 2016 to 2018 and ranked 42nd by U.S. magazine Pharm Exec’s “Top 50 Companies 2019”. As a recognition for his efforts in promoting the development of the pharmaceutical industry in China, Mr. Tse was awarded a number of honours, including the prize of “World Outstanding Chinese” and an honorary Doctor Degree by the University of West Alabama, United States of America in January 2008, the “2007/2008 Asian Knowledge Management Association academician” granted by the Asian Knowledge Management Association in December 2008, and the “The Top Ten Most Leading Innovative Persons of the PRC Enterprises in 2010” jointly granted by the PRC Productivity Society and the PRC Corporation Press in June 2010. Mr. Tse was a member of the Ninth, Tenth and Eleventh National Committee of the Chinese People’s Political Consultative Conference. He is currently the executive vice chairman of the China Overseas Chinese Entrepreneurs Association and the Beijing Overseas Chinese Chamber of Commerce, and the vice chairman of the China International Council for the Promotion of Multinational Corporations.
  • Executive Director and Vice Chairlady: Ms. Cheng Cheung Ling
    is the vice chairwoman of the Board, an executive director, and a member of the executive board committee of the Company. She is the chairwoman of Beijing Tide and CP Qingdao. Ms. Cheng graduated from the Guanghua School of Management of Peking University and obtained a Master Degree in Business Administration. She is a also clinician. Ms. Cheng is one of the founders of CP Pharmaceutical Group and has made significant contribution to the development of business of the group in China. Having extensive experience in and a discerning vision for management and investment in the pharmaceutical industry, she spares no effort in promoting innovation and research and development capabilities in the industry. Being at the helm of Beijing Tide, Ms. Cheng advocates for innovations in research and development, production, sales, and management, and has led Beijing Tide to step up its efforts in developing international collaboration, with an aim to promote the rapid development of cutting-edge technologies for medical products in China. Under her leadership, Beijing Tide has achieved tremendous growth, riding on internationalization and innovation. Beijing Tide has become a leading company for the development of targeted drugs in China, ranked 41st among the “Top 100 Pharmaceutical Companies in China” for 2018 (awarded by the China National Pharmaceutical Industry Information Center) and recognized as an “Outstanding Industrial Enterprise for Pharmaceutical research and development Pipelines in China” for 2019 (awarded by the National Pharmaceutical Industry Information Annual Conference). Over the years, Ms. Cheng is committed to facilitating communication and trade between Mainland China and Hong Kong, and has done remarkable work for the purposes of promoting national cohesion and attracting investments in Hong Kong and Mainland China. She is also a devoted charity supporter, actively participating in and caring for community philanthropy. The distinguished community services provided by Ms. Cheng is well recognized by various domestic and overseas organisations. She has been appointed as a Justice of the Peace by the Government of Hong Kong SAR and awarded by a number of organizations honours such as “The 11th session of the Qindao award of Qingdao City”, “A Pioneer in Pharmaceutical Industry in China for 2019”, and one of the “Top 10 Leaders in Economy in China for 2019”. Public offices held by Ms. Cheng include being the chairwoman of the Friendship Association of the Political Consultative Conference (Hong Kong Provincial Committee), a member of the Eighth, Ninth, Tenth, Eleventh and Twelfth Standing Committees of the Shaanxi Province Chinese People’s Political Consultative Conference (and the convenor of its committee members in Hong Kong), the president of Hong Kong Belt and Road General Chamber of Commerce, and the vice president of the China Female Entrepreneurs Association.
  • Executive Director: Mr. Tse, Eric S Y
    is an executive director and a member of the executive board committee of the Company and the chairman of CT Tianqing. He holds a Bachelor of Science degree in Economics from the Wharton School of the University of Pennsylvania and a master degree in Management and Global Leadership from Schwarzman College, Tsinghua University. Before joining the Company in June 2018, Mr. Tse, Eric S Y served as the chief executive officer of Liepin North America, a reputable human resources company. Mr. Tse, Eric S Y founded the Penn Wharton China Summit during his time at university, and established the China Summit Foundation at the end of 2016. He was awarded the “Top Ten Outstanding Chinese American Youth” in 2018 (the list of which was jointly selected by the All America Chinese Youth Federation, the American Chinese Public Diplomacy Association, and the English “Los Angeles Post”).
  • Executive Director and Chief Executive Officer: Mr. Li Yi
    is an executive director and chief executive officer of the Company. He joined J.P. Morgan China in October 2014 as chairman and chief executive officer, overseeing the overall operations of the group’s business in China and chairing its China management committee. Mr. Li focused on building a strong and comprehensive professional management team to support the all-around healthy development of J.P. Morgan’s business in China from a long-term strategic perspective. Mr. Li was appointed as the chairman of J.P. Morgan Chase Bank (China) Company Limited in April 2015, and was promoted to vice chairman of Global Banking, J.P. Morgan in May 2018, dedicated to improving the degree of internationalization of China capital market and the level of Chinese enterprises’ involvement in international capital markets. In September 2019, Mr. Li assumed the role of chairman of J.P. Morgan Securities (China) Company Limited, which was the first newly established foreign controlled joint venture securities company in China. Before joining J.P. Morgan, Mr. Li served as the chairman and country head of UBS China, and the chairman of UBS Securities Co., Ltd. Under the leadership of Mr. Li, UBS successfully established the first Sino-foreign fully licensed securities joint venture company in China, and built various China platforms such as securities, banking, wealth management, asset management and futures and options. From 2001 to 2005, Mr. Li was the managing director of China Merchants Holdings (International) Company Limited; during that period, the company’s overall performance increased by approximately four times and the company was included in the Hang Seng Index in 2004. In 2004, Mr. Li was selected as one of the “Most Outstanding Business Leaders in Asia” by CNBC Asia. In 2016, leveraging on his “strategy-driven” management concept and effective management, Mr. Li became the only one in the industry named as the “Chinese Investment Banker in Ten Years” by China Business Network. In 2018, Mr. Li was granted the “Global Multinational Corporation Leaders Outstanding Contribution Award” by the China International Council for the Promotion of Multinational Corporations. From 1976 to 1980, Mr. Li was a professional soccer player. Mr. Li graduated from Wharton School of the University of Pennsylvania with an MBA degree. Before that, he graduated and holds a bachelor’s degree in law from China University of Political Science and Law, as well as a bachelor’s degree from Beijing Sport University.
  • Executive Director: Mr. Tse Hsin
    is an executive director and a vice president of the Company. He is mainly responsible for the acquisition and merger activities of the Group. He is also the Group’s spokesman. Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor’s Degree (Honors) in Industrial Engineering. He joined the Group in August, 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd. Mr. Tse Hsin was a council member of the first council and the executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He is also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, the vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, the executive member of the third committee of the Shaanxi Cancer Fighting Association and the vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee. He was awarded the “Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province” by the Shaanxi Provincial Government and the “Outstanding entrepreneur who cares about his staff” by the Shaanxi Foreign Invested Enterprises Association. He was a director of CT Tianqin and Beijing Tide, and is currently a director of NJCTT and CP Qingdao, a supervisor of CT Tianqing, and the president of Chia Tai Shaoyang Orthopedic Hospital.
  • Executive Director: Ms. Li Mingqin
    is currently a vice president of the Company and a director of Beijing Tide, Chia Tai Shaoyang Orthopedic Hospital, CP Boai Investment Ltd., and Jiangsu CT Qingjiang, and is principally responsible for the investment affairs of the Group. Ms. Li graduated from the Faculty of Medicine of Beijing Chinese Medicine University with a Bachelor Degree in medicine. Prior to joining the Company, Ms. Li had worked in Sino-Japanese Friendly Hospital and Beijing Chinese Medicine University, engaged in teaching of medicines, development of new medicines and medicine management. During the period from 1992 to 1995, Ms. Li had been engaged in post-doctorate research in the Medicine School of University of Colorado, USA and the Medical College of the University of Massachusetts. Ms. Li joined the Group in March, 1997 and has 37 years of experience in the pharmaceutical industry.
  • Executive Director: Mr. Wang Shanchun
    is the president of CT Tianqing. He graduated from Nanjing University of Chemistry in July, 1990 and joined CT Tianqing in the same year. Mr. Wang studied pharmaceutical engineering with Tianjin University from 1999 to 2002 and obtained a Master Degree. Mr. Wang has extensive management experience in the PRC pharmaceutical field. His design of the new production plant of CT Tianqing in Haizhou achieved a number of innovations in the country and obtained the first new edition national GMP certificate. He was awarded as a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Technology Advancement First Honour Award, a Jiangsu Province Outstanding Entrepreneur, a Jiangsu Province Young and Middle-aged Expert with Outstanding Contribution, a Jiangsu Advanced Individual with Outstanding Contribution in Manufacture, and a National Distinguished Leader in Pharmaceutical Quality Management, and was elected as a delegate to Committee of the 13th Chinese People’s Political Consultative Conference of Jiangsu Province.
  • Executive Director: Mr. Tian Zhoushan
    joined the Group in April, 1997 and is responsible for the business of NJCTT. Mr. Tian is currently the general manager of NJCTT. Mr. Tian completed MBA coursework in Nanjing University. He was the head of production, the assistant to the president, and the vice president of CT Tianqing, and has over 30 years of experience in the pharmaceutical industry.
  • Independent Non-Executive Directors: Mr. Lu Zhengfei
    is an independent non-executive director of the Company and is the chairman of the audit committee and a member of the remuneration committee and the nomination committee of the Company. He received a P.h.D. Degree in Economics (financial management). Mr. Lu is currently a Distinguished Professor of Chang Jiang Scholars and supervisor of doctoral students of the Guanghua School of Management of Peking University. He had previously held various senior positions in the Department of Accounting of both the Guanghua School of Management of Peking University and the Nanjing University. He is a standing council member of the China Accounting Association and the deputy director of its Financial Management Committee and was also an expert consultant of the China Financial Accounting Standards Board, Ministry of Finance. Mr. Lu is the editor of several accounting and finance journals and has issued various publications. He is an independent director of China Cinda Asset Management Co., Ltd. and an independent supervisor of PICC Property and Casualty Company Limited, both companies being listed on the Stock Exchange, and was an independent director of Bank of China Limited (listed on the Stock Exchange) and China Nuclear Engineering and Construction Corporation Limited (listed on Shanghai Stock Exchange).
  • Independent Non-Executive Directors: Mr. Li Dakui
    joined the Company as an independent non-executive director and a member of the audit committee of the Company in September, 2004. He graduated from the Faculty of Pharmacy of Beijing Medical University (now known as the School of Pharmaceutical Sciences of Beijing University) in 1965, and obtained a Master Degree in Pharmaceutics from Peking Union Medical College (“PUMC”) in 1982. He used to be the chief pharmacist of PUMC Hospital (retired in 2013) and the director of Pharmacy Department of PUMC Hospital for years. Mr. Li was a vice president of the Chinese Pharmaceutical Association, the Chairman of the Committee of Hospital Pharmacy Branch of Chinese Pharmaceutical Association and the vice chairman of the Chinese Practicing Pharmacist Association. He is currently an advisory member of the Chinese Pharmaceutical Committee and a vice president of the Beijing Pharmaceutical Association.
  • Independent Non-Executive Directors: Ms. Lu Hong
    joined the Company as an independent non-executive director and a member of the audit committee, the remuneration committee and the nomination committee of the Company in April, 2015. Ms. Lu has over 20 years of experience in accounting, financial management, company secretary and domestic and overseas capital operations fields. She is a member of the Chinese Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Ms. Lu has extensive knowledge of PRC and international accounting standards and the listing rules and regulations of both Hong Kong and PRC. She has been in charge of or involved in the entire process of the listing of multiple corporations in the PRC, Hong Kong, Singapore and the United States of America and quite a number of foreign and domestic investment and financing operations as well as mergers and acquisitions. She is familiar with financial analysis, budgeting, financial management and tax planning. She also has expertise in dealing with complex financing and taxation matters. Ms. Lu is an independent non-executive director of Huan Yue Interactive Holdings Limited which is listed on the Stock Exchange.
  • Independent Non-Executive Directors: Mr. Zhang Lu Fu
    joined the Company as an independent non-executive director and the chairman of the remuneration committee and a member of the nomination committee of the Company in April, 2015. Mr. Zhang holds a Master Degree in Philosophy from the Beijing Normal University, and is currently a research associate and a part-time professor. Mr. Zhang has been working for multiple sectors of the Chinese government since 1987, including the Hong Kong branch of the Xin Hua News Agency (now known as Liaison Office of the Central People’s Government in Hong Kong). Mr. Zhang has worked for a number of Hong Kong listed companies and charitable organisations on full-time and part-time bases. Mr. Zhang is a council member of the China Overseas Friendship Association, a standing council member of the Guangdong Overseas Friendship Association, a standing council member of the Shenzhen Overseas Friendship Association, and a part-time professor of the Hong Kong Academy of Management, and was a member of the Shenzhen Committee of the 4th Chinese People’s Political Consultative Conference. Mr. Zhang is an independent non-executive director of Kingboard Laminates Holdings Limited and CT Environmental Group Limited, both being listed on the Stock Exchange.
  • Independent Non-Executive Directors: LI Kwok Tung Donald
    Dr. LI Kwok Tung Donald (SBS, JP), joined the Company as an independent non-executive director and a member of the audit committee and nomination committee, respectively, of the Company in December, 2020. Dr. Li is a specialist in family medicine in private practice in Hong Kong. He is the president of the World Organisation of Family Physicians (WONCA), the past president of the Hong Kong Academy of Medicine and the censor of the Hong Kong College of Family Physicians. He was also the chairman of the governing board of Hong Kong Jockey Club Disaster Preparedness and Response Institute of the Hong Kong Academy of Medicine. Dr. Li graduated with a bachelor of arts degree from Cornell University, USA, in 1975 and followed by his study in medicine, he obtained a bachelor of medicine from the University of Hong Kong in 1980. He is a fellow of The Hong Kong College of General Practitioners, fellow of the Hong Kong Academy of Medicine, honorary fellow of the Hong Kong College of Dental Surgeons, honorary fellow of the Royal Australian College of General Practitioners, honorary fellow of the Hong Kong College of Family Physicians, fellow of the Faculty of Public Health of the Royal College of Physicians of the United Kingdom, honorary fellow of the Academy of Family Physicians of Malaysia, registered Mainland China medical practitioner, fellow of the American College of Physicians, honorary fellow of the Royal College of Physicians of Thailand, fellow of the Academy of Medicine, Singapore, honorary fellow of the Royal College of Physicians of Ireland, and honorary fellow of the Royal College of General Practitioners. Dr. Li is an honorary clinical professor in family medicine of the Chinese University of Hong Kong, honorary professor in the Faculty of Medicine of the University of Hong Kong, and the adjunct associate professor of the Faculty of Health Science of Macau University of Science and Technology. He is the chairman of the Action Committee Against Narcotics, the director of the Hong Kong St. John Ambulance Association, the chairman of the Hong Kong Sheng Kung Hui Welfare Council and the honorary steward of the Hong Kong Jockey Club. He is also the honorary adviser of The Hong Kong Award for Young People, the chairman of the Professional Committee on Medical Health of Belt and Road General Chamber of Commerce in Hong Kong, a member of the Chief Executive’s Council of Advisers on Innovation and Strategic Development and a member of the steering committee on Primary Healthcare Development of Food and Health Bureau in Hong Kong. Dr. Li is an independent non-executive director of C-MER Eye Care Holdings Limited, UMP Healthcare Holdings Limited, and New Horizon Health Limited, which are listed on the Stock Exchange.